Sarepta Therapeutics (SRPT) Net Cash Flow (2010 - 2026)
Sarepta Therapeutics' quarterly Net Cash Flow came in at -$336.8 million in Q1 2026, up 60.93% year-on-year from -$209.3 million in Q1 2025, and down 278.97% quarter-over-quarter from $188.2 million in Q4 2025.
Sarepta Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at -$336.8 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 60.93% year-over-year to -$336.8 million; the trailing twelve-month figure through Mar 2026 stood at $221.1 million (up 218.62% YoY), and the FY2025 full-year result was -$304.2 million, down 145.09% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$336.8 million, down from $188.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $905.2 million in Q4 2024, with the low at -$882.0 million in Q1 2022.
- Average Net Cash Flow over 5 years is -$96.9 million, with a median of -$71.8 million recorded in 2022.
- Year-over-year, Net Cash Flow jumped 873.16% in 2024 and sank 75526.58% in 2025.
- Tracing SRPT's Net Cash Flow over 5 years: stood at -$71.8 million in 2022, then plunged by 62.95% to -$117.1 million in 2023, then jumped by 873.16% to $905.2 million in 2024, then tumbled by 79.21% to $188.2 million in 2025, then slumped by 278.97% to -$336.8 million in 2026.
- The last three Net Cash Flow figures came in at -$336.8 million (Q1 2026), $188.2 million (Q4 2025), and $100.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | -336.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -336.83 Mn |
| Mar 31, 2026 | -336.83 Mn |
| Dec 31, 2025 | 188.21 Mn |
| Dec 31, 2025 | 188.21 Mn |
| Sep 30, 2025 | 100.03 Mn |
| Sep 30, 2025 | 100.03 Mn |
| Jun 30, 2025 | 269.73 Mn |
| Jun 30, 2025 | 269.73 Mn |
| Mar 31, 2025 | -862.14 Mn |
| Mar 31, 2025 | -862.14 Mn |
| Dec 31, 2024 | 905.16 Mn |
| Dec 31, 2024 | 905.16 Mn |
| Sep 30, 2024 | -185.77 Mn |
| Sep 30, 2024 | -185.77 Mn |
| Jun 30, 2024 | -43.67 Mn |
| Jun 30, 2024 | -43.67 Mn |
| Mar 31, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.14 Mn |
| Dec 31, 2023 | -117.07 Mn |
| Dec 31, 2023 | -117.07 Mn |
| Sep 30, 2023 | -309.87 Mn |
| Sep 30, 2023 | -309.87 Mn |
| Jun 30, 2023 | -19.74 Mn |
| Jun 30, 2023 | -19.74 Mn |
| Mar 31, 2023 | -95.11 Mn |
| Mar 31, 2023 | -95.11 Mn |
| Dec 31, 2022 | -71.85 Mn |
| Dec 31, 2022 | -71.85 Mn |
| Sep 30, 2022 | 170.58 Mn |
| Sep 30, 2022 | 170.58 Mn |
| Jun 30, 2022 | -356.47 Mn |
| Jun 30, 2022 | -356.47 Mn |
| Mar 31, 2022 | -881.99 Mn |
| Mar 31, 2022 | -881.99 Mn |
| Dec 31, 2021 | 517.35 Mn |
| Dec 31, 2021 | 517.35 Mn |
| Sep 30, 2021 | -98.16 Mn |
| Sep 30, 2021 | -98.16 Mn |
| Jun 30, 2021 | 215.44 Mn |
| Jun 30, 2021 | 215.44 Mn |
| Mar 31, 2021 | -20.81 Mn |
| Mar 31, 2021 | -20.81 Mn |
| Dec 31, 2020 | 28.51 Mn |
| Dec 31, 2020 | 28.51 Mn |
| Sep 30, 2020 | -165.32 Mn |
| Sep 30, 2020 | -165.32 Mn |
| Jun 30, 2020 | -124.25 Mn |
| Jun 30, 2020 | -124.25 Mn |
| Mar 31, 2020 | 929.13 Mn |
| Mar 31, 2020 | 929.13 Mn |
| Dec 31, 2019 | 110.25 Mn |
| Dec 31, 2019 | 110.25 Mn |
| Sep 30, 2019 | -83.66 Mn |
| Sep 30, 2019 | -83.66 Mn |
| Jun 30, 2019 | 79.66 Mn |
| Jun 30, 2019 | 79.66 Mn |
| Mar 31, 2019 | 366.56 Mn |
| Mar 31, 2019 | 366.56 Mn |
| Dec 31, 2018 | 161.13 Mn |
| Dec 31, 2018 | 161.13 Mn |
| Sep 30, 2018 | -200.67 Mn |
| Sep 30, 2018 | -200.67 Mn |
| Jun 30, 2018 | -147.00 Mn |
| Jun 30, 2018 | -147.00 Mn |
| Mar 31, 2018 | -42.46 Mn |
| Mar 31, 2018 | -42.46 Mn |
| Dec 31, 2017 | -17.94 Mn |
| Dec 31, 2017 | -17.94 Mn |
| Sep 30, 2017 | 449.28 Mn |
| Sep 30, 2017 | 449.28 Mn |
| Jun 30, 2017 | -106.38 Mn |
| Jun 30, 2017 | -106.38 Mn |
| Mar 31, 2017 | 152.30 Mn |
| Mar 31, 2017 | 152.30 Mn |
| Dec 31, 2016 | -272.72 Mn |
| Dec 31, 2016 | -272.72 Mn |
| Sep 30, 2016 | 283.32 Mn |
| Sep 30, 2016 | 283.32 Mn |
| Jun 30, 2016 | 73.82 Mn |
| Jun 30, 2016 | 73.82 Mn |
| Mar 31, 2016 | -42.30 Mn |
| Mar 31, 2016 | -42.30 Mn |
| Dec 31, 2015 | 24.49 Mn |
| Dec 31, 2015 | 24.49 Mn |
| Sep 30, 2015 | -13.72 Mn |
| Sep 30, 2015 | -13.72 Mn |
| Jun 30, 2015 | -4.90 Mn |
| Jun 30, 2015 | -4.90 Mn |
| Mar 31, 2015 | 885,000.00 |
| Mar 31, 2015 | 885,000.00 |
| Dec 31, 2014 | 21.25 Mn |
| Dec 31, 2014 | 21.25 Mn |
| Sep 30, 2014 | -50.46 Mn |
| Sep 30, 2014 | -50.46 Mn |
| Jun 30, 2014 | 53.65 Mn |
| Jun 30, 2014 | 53.65 Mn |
| Mar 31, 2014 | -207.86 Mn |
| Mar 31, 2014 | -207.86 Mn |
| Dec 31, 2013 | -16.68 Mn |
| Dec 31, 2013 | -16.68 Mn |
| Sep 30, 2013 | 117.46 Mn |
| Sep 30, 2013 | 117.46 Mn |
| Jun 30, 2013 | -11.73 Mn |
| Jun 30, 2013 | -11.73 Mn |
| Mar 31, 2013 | -19.74 Mn |
| Mar 31, 2013 | -19.74 Mn |
| Dec 31, 2012 | 149.67 Mn |
| Dec 31, 2012 | 149.67 Mn |
| Sep 30, 2012 | 13.50 Mn |
| Sep 30, 2012 | 13.50 Mn |
| Jun 30, 2012 | -6.08 Mn |
| Jun 30, 2012 | -6.08 Mn |
| Mar 31, 2012 | -9.33 Mn |
| Mar 31, 2012 | -9.33 Mn |
| Dec 31, 2011 | -6.45 Mn |
| Dec 31, 2011 | -6.45 Mn |
| Sep 30, 2011 | -7.83 Mn |
| Sep 30, 2011 | -7.83 Mn |
| Jun 30, 2011 | 30.91 Mn |
| Jun 30, 2011 | 30.91 Mn |
| Mar 31, 2011 | -10.31 Mn |
| Mar 31, 2011 | -10.31 Mn |
| Dec 31, 2010 | -2.38 Mn |
| Dec 31, 2010 | -2.38 Mn |
| Sep 30, 2010 | -775,000.00 |
| Sep 30, 2010 | -775,000.00 |